{"id":8550,"date":"2026-08-21T12:50:49","date_gmt":"2026-08-21T09:50:49","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8550"},"modified":"2026-08-21T12:50:52","modified_gmt":"2026-08-21T09:50:52","slug":"hlb-panagene-pna-aoc-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/hlb-panagene-pna-aoc-dmd\/","title":{"rendered":"HLB Panagene Duchenne Kas Distrofisi \u0130\u00e7in Yeni Bir Yakla\u015f\u0131m Olarak PNA-AOC&#039;ye Y\u00f6neliyor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Duchenne kas distrofisi (DMD), bir\u00e7ok tedavi yakla\u015f\u0131m\u0131n\u0131n kabul edilebilir bir g\u00fcvenlik profili korurken iskelet ve kalp kas\u0131na yeterli miktarda tedavi sa\u011flamakta zorlanmas\u0131 nedeniyle ila\u00e7 geli\u015ftiriciler i\u00e7in b\u00fcy\u00fck bir zorluk olmaya devam etmektedir. <strong>Bu ba\u011flamda, G\u00fcney Koreli biyoteknoloji \u015firketi HLB Panagene, peptit n\u00fckleik asit (PNA) tabanl\u0131 antikor-oligon\u00fckleotid konjugat\u0131 (AOC) platformuna dayal\u0131 farkl\u0131 bir strateji ara\u015ft\u0131r\u0131yor.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AOC, antikor-ila\u00e7 konjugatlar\u0131 (ADC) kavram\u0131ndan t\u00fcretilen yeni bir tedavi y\u00f6ntemidir. Geleneksel sitotoksik bir ila\u00e7 ta\u015f\u0131mak yerine, AOC, n\u00fckleik asit bazl\u0131 terap\u00f6tik bir y\u00fck\u00fc belirli h\u00fccrelere iletmek i\u00e7in bir antikor kullan\u0131r. Ama\u00e7, antikorlar\u0131n hedefleme yetene\u011fini, n\u00fckleik asitlerin gen ekspresyonunu d\u00fczenleme yetene\u011fiyle birle\u015ftirmektir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">N\u00fckleik asit bazl\u0131 terap\u00f6tik ila\u00e7lar\u0131n en b\u00fcy\u00fck zorluklar\u0131ndan biri de ila\u00e7 iletimidir. Bu molek\u00fcllerin h\u00fccre zarlar\u0131n\u0131 ge\u00e7me yetenekleri genellikle s\u0131n\u0131rl\u0131d\u0131r. Antikor arac\u0131l\u0131 iletim yoluyla h\u00fccrelere girseler bile, hedeflenen h\u00fccre i\u00e7i noktaya ula\u015fmadan \u00f6nce endozomlar\u0131n i\u00e7inde hapsolabilir veya par\u00e7alanabilirler. <strong>HLB Panagene, PNA&#039;n\u0131n yap\u0131sal stabilitesi ve g\u00fc\u00e7l\u00fc hedef ba\u011flama \u00f6zellikleri nedeniyle bu s\u0131n\u0131rlamalar\u0131n baz\u0131lar\u0131n\u0131 gidermeye yard\u0131mc\u0131 olabilece\u011fine inanmaktad\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u015eirket, PNA-AOC platformunun do\u011frulanmas\u0131 i\u00e7in ilk hastal\u0131k endikasyonu olarak DMD&#039;yi se\u00e7ti.<\/strong> Bu yakla\u015f\u0131m, \u00f6zellikle bir oligon\u00fckleotidin distrofin \u00f6n-mRNA i\u015flenmesini de\u011fi\u015ftirmek ve h\u00fccrelerin daha k\u0131sa ancak potansiyel olarak i\u015flevsel bir distrofin proteini \u00fcretmesine olanak sa\u011flamak \u00fczere tasarland\u0131\u011f\u0131 ekson atlama terapisi i\u00e7in \u00f6nemlidir. HLB Panagene, ekson atlama PNA&#039;s\u0131n\u0131n kas dokusuna iletimini iyile\u015ftirmeyi ama\u00e7layan bir AOC mimarisi \u00fczerinde \u00e7al\u0131\u015fmaktad\u0131r. <strong>Sekt\u00f6r raporlar\u0131, transferrin resept\u00f6r\u00fc 1 (TfR1) antikorunun, uygulama stratejisinin bir par\u00e7as\u0131 olarak ara\u015ft\u0131r\u0131ld\u0131\u011f\u0131n\u0131 ve 2026 y\u0131l\u0131 i\u00e7in klinik \u00f6ncesi kavram kan\u0131t\u0131 \u00e7al\u0131\u015fmas\u0131n\u0131n hedeflendi\u011fini g\u00f6stermektedir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu strateji, mevcut bir\u00e7ok DMD tedavi yakla\u015f\u0131m\u0131n\u0131n etkinlik, uygulama veya g\u00fcvenlik konular\u0131nda s\u0131n\u0131rlamalarla kar\u015f\u0131la\u015fmas\u0131 \u00fczerine ortaya \u00e7\u0131kt\u0131.<\/strong> Di\u011fer \u015firketler de AOC tabanl\u0131 programlar da dahil olmak \u00fczere hedefli oligon\u00fckleotid da\u011f\u0131t\u0131m teknolojileri geli\u015ftiriyor; bu da da\u011f\u0131t\u0131m verimlili\u011finin yeni nesil DMD ila\u00e7 geli\u015ftirmenin en \u00f6nemli m\u00fccadele alanlar\u0131ndan biri haline geldi\u011fini g\u00f6steriyor.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metot<\/th><th>Y\u00fck<\/th><th>Teslimat stratejisi<\/th><th>DMD hedefi<\/th><th>Geli\u015fim a\u015famas\u0131<\/th><\/tr><\/thead><tbody><tr><td>Geleneksel ekzon atlama<\/td><td>PMO<\/td><td>Sistemik<\/td><td>Belirli eksonlar<\/td><td>Onayl\u0131<\/td><\/tr><tr><td>AOC yakla\u015f\u0131m\u0131<\/td><td>Oligon\u00fckleotid<\/td><td>Antikor arac\u0131l\u0131<\/td><td>Kas<\/td><td>Klinik geli\u015ftirme<\/td><\/tr><tr><td>PNA-AOC<\/td><td>PNA<\/td><td>Antikor arac\u0131l\u0131<\/td><td>Kas<\/td><td>Erken\/klinik \u00f6ncesi<\/td><\/tr><tr><td>Gen terapisi<\/td><td>Mikrodistrofin<\/td><td>Ortalama ortalama<\/td><td>Geni\u015f kas<\/td><td>\u00dcr\u00fcne ba\u011fl\u0131 olarak klinik\/onayl\u0131<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ancak HLB Panagene&#039;nin PNA-AOC program\u0131 hen\u00fcz ba\u015flang\u0131\u00e7 a\u015famas\u0131ndad\u0131r.<\/strong> \u015eu anda DMD i\u00e7in onaylanm\u0131\u015f bir PNA-AOC tedavisi bulunmamaktad\u0131r ve \u015firketin yakla\u015f\u0131m\u0131n\u0131n insan \u00e7al\u0131\u015fmalar\u0131nda etkili kas i\u00e7i uygulama, ekson atlama aktivitesi, distrofin restorasyonu, g\u00fcvenlik ve nihayetinde klinik fayda sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6stermesi gerekmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dolay\u0131s\u0131yla, DMD aileleri i\u00e7in PNA-AOC, mevcut bir tedavi y\u00f6ntemi olarak de\u011fil, izlenmeye de\u011fer deneysel bir tedavi platformu olarak g\u00f6r\u00fclmelidir.<\/strong> Potansiyel \u00f6nemi, n\u00fckleik asit terapilerinin kar\u015f\u0131 kar\u015f\u0131ya oldu\u011fu temel sorunlardan birini \u00e7\u00f6zmeye \u00e7al\u0131\u015fmas\u0131nda yatmaktad\u0131r: do\u011fru tedavi edici molek\u00fcl\u00fc do\u011fru kas h\u00fccrelerine etkili ve s\u00fcrd\u00fcr\u00fclebilir bir d\u00fczeyde ula\u015ft\u0131rmak.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eimdi Ke\u015ffedin: <a href=\"https:\/\/dmdwarrior.com\/clinical-trials\/\">DMD Klinik Ara\u015ft\u0131rmalar\u0131<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Duchenne muscular dystrophy (DMD) remains a major challenge for drug developers because many therapeutic approaches have struggled to deliver sufficient amounts of a treatment to skeletal and cardiac muscle while maintaining an acceptable safety profile. Against this backdrop, South Korean biotechnology company HLB Panagene is exploring a different strategy based on a peptide nucleic acid [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":8551,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[872,873,158],"class_list":["post-8550","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-hlb-panagene","tag-pna-aoc","tag-south-korea"],"subtitle":"Duchenne kas distrofisi (DMD) tedavisi, hedefe y\u00f6nelik ila\u00e7 da\u011f\u0131t\u0131m\u0131nda yeni bir d\u00f6neme giriyor. HLB Panagene, tedavi hassasiyetini art\u0131rmak i\u00e7in PNA-AOC teknolojisini ara\u015ft\u0131r\u0131yor. Bu yakla\u015f\u0131m, DMD tedavisinin en b\u00fcy\u00fck zorluklar\u0131ndan biri olan do\u011fru tedaviyi kas h\u00fccrelerine ula\u015ft\u0131rma sorununu a\u015fabilir mi?","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8550"}],"version-history":[{"count":1,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8550\/revisions"}],"predecessor-version":[{"id":8552,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8550\/revisions\/8552"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8551"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}